Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
new york blog main
new york top stories
4
×
akcea therapeutics
alnylam pharmaceuticals
boston top stories
clinical trials
drugs
inotersen
national top stories
onpattro
patisiran
pfizer
san diego blog main
san diego top stories
tafamidis
boston
fda
hereditary transthyretin amyloidosis
new york
rna interference
alirocumab
amgen
andrew fire
anylam pharmaceuticals
biotech
cardiomyopathy
craig mello
european medicines agency
evercore isi
evolocumab
harvard pilgrim health care
heart attack
inclisiran
institute for clinical and economic review
john maraganore
joseph swartz
medicines co.
What
alnylam
4
×
drug
4
×
fda
approved
medicine
medicines
pharmaceuticals
rna
rnai
afternoon
ago
akcea
alnylam’s
amyloidosis
approves
attr
available
based
battle
cells
cholesterol
data
debilitating
disease
ema
employ
europe
evidence
follows
gene
genetic
gets
harmful
heart
history
hits
interference
landmark
lasting
long
Language
Current search:
alnylam
×
drug
×
" new york top stories "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug